Changes in prostate apparent diffusion coefficient values during radiotherapy after neoadjuvant hormones

被引:4
作者
McPartlin, Andrew [1 ]
Kershaw, Lucy [2 ]
McWilliam, Alan [1 ]
Ben Taylor, Marcus [1 ]
Hodgson, Clare [1 ]
van Herk, Marcel [1 ]
Choudhury, Ananya [1 ]
机构
[1] Christie NHS Fdn Trust, Wilmslow Rd, Manchester M20 4BX, Lancs, England
[2] Univ Edinburgh, Edinburgh, Midlothian, Scotland
关键词
Prostate; radiotherapy; MRI; DWI; hormone therapy; INTENSITY-MODULATED RADIOTHERAPY; ANDROGEN-DEPRIVATION THERAPY; CANCER; MRI;
D O I
10.1177/1756287218798748
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Changes in prostate cancer apparent diffusion coefficient (ADC) derived from diffusion-weighted magnetic resonance imaging (MRI) provide a noninvasive method for assessing radiotherapy response. This may be attenuated by neoadjuvant hormone therapy (NA-HT). We investigate ADC values measured before, during and after external beam radiotherapy (EBRT) following NA-HT. Methods: Patients with >= T2c biopsy-proven prostate cancer receiving 3 months of NA-HT plus definitive radiotherapy were prospectively identified. All underwent ADC-MRI scans in the week before EBRT, in the third week of EBRT and 8 weeks after its completion. Imaging was performed at 1.5 T. The tumour, peripheral zone (PZ) and central zone (CZ) of the prostate gland were identified and median ADC calculated for each region and time point. Results: Between September and December 2014, 15 patients were enrolled (median age 68.3, range 57-78) with a median Gleason score of 7 (6-9) and prostate-specific antigen (PSA) at diagnosis 14 (3-197) ng/ml. Median period of NA-HT prior to first imaging was 96 days (69-115). All patients completed treatment. Median follow up was 25 months (7-34), with one patient relapsing in this time. Thirteen patients completed all imaging as intended, one withdrew after one scan and another missed the final imaging. PZ and CZ could not be identified in one patient. Median tumour ADC before, during and post radiotherapy was 1.24 x 10(-3) mm(2)/s (interquartile range 0.16 x 10(-3) mm(2)/s), 1.31 x 10(-3) mm(2)/s (0.22 x 10(-3) mm(2)/s), then 1.32 x 10(-3) mm(2)/s (0.13 x 10(-3) mm(2)/s) respectively (p > 0.05). There was no significant difference between median tumour and PZ or CZ ADC at any point. Gleason score did not correlate with ADC values. Conclusions: Differences in ADC parameters of normal and malignant tissue during EBRT appear attenuated by prior NA-HT. The use of changes in ADC as a predictive tool in this group may have limited utility.
引用
收藏
页码:359 / 364
页数:6
相关论文
共 23 条
  • [1] DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A feasibility study
    Barrett, T.
    Gill, A. B.
    Kataoka, M. Y.
    Priest, A. N.
    Joubert, I.
    McLean, M. A.
    Graves, M. J.
    Stearn, S.
    Lomas, D. J.
    Griffiths, J. R.
    Neal, D.
    Gnanapragasam, V. J.
    Sala, E.
    [J]. MAGNETIC RESONANCE IN MEDICINE, 2012, 67 (03) : 778 - 785
  • [2] Pathologic effects of Neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma - A detailed analysis of radical prostatectomy specimens from a randomized trial
    Bullock, MJ
    Srigley, JR
    Klotz, LH
    Goldenberg, SL
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (11) : 1400 - 1413
  • [3] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
    Dearnaley, David
    Syndikus, Isabel
    Sumo, Georges
    Bidmead, Margaret
    Bloomfield, David
    Clark, Catharine
    Gao, Annie
    Hassan, Shama
    Horwich, Alan
    Huddart, Robert
    Khoo, Vincent
    Kirkbride, Peter
    Mayles, Helen
    Mayles, Philip
    Naismith, Olivia
    Parker, Chris
    Patterson, Helen
    Russell, Martin
    Scrase, Christopher
    South, Chris
    Staffurth, John
    Hall, Emma
    [J]. LANCET ONCOLOGY, 2012, 13 (01) : 43 - 54
  • [4] Intensity-modulated radiotherapy of the prostate: Dynamic ADC monitoring by DWI at 3.0 T
    Decker, Georges
    Muertz, Petra
    Gieseke, Jurgen
    Traeber, Frank
    Block, Wolfgang
    Sprinkart, Alois M.
    Leitzen, Christina
    Buchstab, Timo
    Lutter, Christiana
    Schueller, Heinrich
    Schild, Hans H.
    Willinek, Winfried A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 113 (01) : 115 - 120
  • [5] Prostate MRI: Evaluating Tumor Volume and Apparent Diffusion Coefficient as Surrogate Biomarkers for Predicting Tumor Gleason Score
    Donati, Olivio F.
    Afaq, Asim
    Vargas, Hebert Alberto
    Mazaheri, Yousef
    Zheng, Junting
    Moskowitz, Chaya S.
    Hricak, Hedvig
    Akin, Oguz
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (14) : 3705 - 3711
  • [6] Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer
    Foltz, Warren D.
    Wu, Andy
    Chung, Peter
    Catton, Charles
    Bayley, Andrew
    Milosevic, Michael
    Bristow, Robert
    Warde, Padraig
    Simeonov, Anna
    Jaffray, David A.
    Haider, Masoom A.
    Menard, Cynthia
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2013, 37 (04) : 909 - 916
  • [7] Repeatability of echo-planar-based diffusion measurements of the human prostate at 3 T
    Gibbs, Peter
    Pickles, Martin D.
    Turnbull, Lindsay W.
    [J]. MAGNETIC RESONANCE IMAGING, 2007, 25 (10) : 1423 - 1429
  • [8] The effect of hormonal treatment on conspicuity of prostate cancer: Implications for focal boosting radiotherapy
    Groenendaal, Greetje
    van Vulpen, Marco
    Pereboom, Susanne R.
    Poelma-Tap, Davey
    Korporaal, Johannes G.
    Monninkhof, Evelyn
    van der Heide, Uulke A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2012, 103 (02) : 233 - 238
  • [9] Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI
    Hoetker, Andreas M.
    Mazaheri, Yousef
    Zheng, Junting
    Moskowitz, Chaya S.
    Berkowitz, Joshua
    Lantos, Joshua E.
    Pei, Xin
    Zelefsky, Michael J.
    Hricak, Hedvig
    Akin, Oguz
    [J]. EUROPEAN RADIOLOGY, 2015, 25 (09) : 2665 - 2672
  • [10] Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer
    Kalbasi, Anusha
    Li, Jiaqi
    Berman, Abigail T.
    Swisher-McClure, Samuel
    Smaldone, Marc
    Uzzo, Robert G.
    Small, Dylan S.
    Mitra, Nandita
    Bekelman, Justin E.
    [J]. JAMA ONCOLOGY, 2015, 1 (07) : 897 - 906